Assorted News from the Last Week: This edition of the CAC2 blog post provides a compassionate guide to embracing bereaved families during the holidays. Columbia
Assorted News from the Last Week: The impact of focused federal initiatives on pediatric cancer research: continuous support for both CCDI and the STAR Act
Assorted News from the Last Week: CAC2 Supporting Organization Member Syndax Pharmaceuticals announced that the Food and Drug Administration approved revumenib, a menin inhibitor, for
Assorted News from the Last Week: This edition of the CAC2 blog post addresses how childhood cancer affects the academic success of school-aged siblings. Iopofosine-131
Assorted News from the Last Week: South African authorities have suspended eight pupils linked to a case of alleged bullying of a childhood cancer patient
Assorted News from the Last Week: U.S. policy changes mean Canadian children with cancer are losing access to clinical trials. Sensitisation, early detection: The lifeline
Assorted News from the Last Week: This edition of the CAC2 blog post addresses the needs of children impacted by an education interruption due to
Assorted News from the Last Week: Following an Executive Order by President Trump, the U.S. Department of Health and Human Services announced a doubling of
Assorted News from the Last Week: Childhood cancer cases are on the rise across the EU. Zebrafish models offer fast, effective guidance for personalized therapies
Assorted News from the Last Week: NCI explains the transition of pediatric brain tumor trials to the PEP-CTN. Up to 10% of pediatric hematologic malignancies
